Bellevue Life Sciences Acquisition Corp.

General Information

We intend to focus our search on companies in the healthcare industry, specifically in the biotechnology sector. (Incorporated in Delaware)

Kuk Hyoun Hwang has been the CEO and a director of the company since March 2020. Mr. Hwang is the managing partner of Bellevue Capital Management (BCM), which he founded in August 2012. BCM, based in Seattle, Washington, is part of the local biotech hub ecosystem of the Greater Seattle area. BCM is also the South Korea advisor for Bellevue Asset Management (BAM), a subsidiary of Bellevue Group AG, a Swiss financial group holding company with global healthcare investing expertise. Bellevue Group AG is publicly listed on the Swiss Exchange (SIX) and oversees assets under management of approximately $11 billion, primarily invested in private and public equities across the global healthcare sector.

(Note: Bellevue Life Sciences Acquisition Corp. priced its SPAC IPO on Feb. 9, 2023, in sync with the terms in the prospectus: 6.0 million units at $10.00 each to raise $60.0 million. At pricing, Bellevue Life Sciences Acquisition Corp. became the fourth SPAC IPO priced so far in 2023. Bellevue Life Sciences Acquisition Corp. filed its S-1 in late April 2022, following a confidential IPO filing in March 2021.)


Employees: 0
Founded: 2020
Contact Information
Address 10900 NE 4th Street, Suite 2300 Bellevue, WA 98004
Phone Number (425) 635-7700
Web Address
View Prospectus: Bellevue Life Sciences Acquisition Corp.
Financial Information
Market Cap $78.9mil
Revenues $0 mil (last 12 months)
Net Income $0 mil (last 12 months)
IPO Profile
Symbol BLACU
Exchange NASDAQ
Shares (millions): 6.0
Price range $10.00 - $10.00
Est. $ Volume $60.0 mil
Manager / Joint Managers Chardan
CO-Managers -
Expected To Trade: 2/10/2023
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change